Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions

Abstract

Nanomaterials have revolutionized medicine by enabling control over drugs’ pharmacokinetics, biodistribution, and biocompatibility. However, most nanotherapeutic batches are highly heterogeneous, meaning they comprise nanoparticles that vary in size, shape, charge, composition, and ligand functionalization. Similarly, individual nanotherapeutics often have heterogeneously distributed components, ligands, and charges. This review discusses nanotherapeutic heterogeneity's sources and effects on experimental readouts and therapeutic efficacy. Among other topics, it demonstrates that heterogeneity exists in nearly all nanotherapeutic types, examines how nanotherapeutic heterogeneity arises, and discusses how heterogeneity impacts nanomaterials’ in vitro and in vivo behavior. How nanotherapeutic heterogeneity skews experimental readouts and complicates their optimization and clinical translation is also shown. Lastly, strategies for limiting nanotherapeutic heterogeneity are reviewed and recommendations for developing more reproducible and effective nanotherapeutics provided.

Single-Particle Spectroscopic Chromatography Reveals Heterogeneous RNA Loading and Size Correlations in Lipid Nanoparticles

“…This suggests that a relatively uniform size distribution, which many studies ,, and industrial efforts have been aiming for in optimizing LNP formulations, does not necessarily translate into a uniform loading distribution. We expect this technical framework can guide the development effort to refine the manufacturing processes to achieve greater compositional homogeneity, which may further enhance the performance of various delivery systems …”

“…We expect this technical framework can guide the development effort to refine the manufacturing processes to achieve greater compositional homogeneity, which may further enhance the performance of various delivery systems. 60 …”

Microenvironment-responsive metal-phenolic network release platform with ROS scavenging, anti-pyroptosis, and ECM regeneration for intervertebral disc degeneration

“…Several antioxidants have been developed to treat ROS-related diseases [ [11] , [12] , [13] ], including IVDD [ 14 ]; however, nanomaterials are more practical because of their better stability under physiological conditions, improved drug utilization, and longer-lasting effects than that of small-molecule compounds [ 15 ]. In addition, the use of nanoparticles (NPs) as drug delivery platforms is conducive to the use of multi-targeted and multifunctional therapies.…”